E6 Vanguard Program - Strategy Lab - Barcelona Edition
Purpose & Context
The Barcelona Strategy Lab is one of five city roundtables in the E6 Concord Six Labs Program, run by the World Technology Congress under the Sovereign Vanguard initiative. E6 Concord (by WTC 2027) proposes major EU capital and sovereignty instruments, considering the official E6 Pillars, including a pan-European Savings & Investments Union; but currently lacks structured, first-hand evidence from the SMEs these instruments are meant to serve. Barcelona runs as a single-industry format, concentrating on Biotech, Healthcare & Pharma given the depth of the local BioRegion ecosystem.
Through this Lab initiative, WTC will generate evidence-based findings that will contribute to the Sovereignty Report to be presented to the European Investment Bank (EIB). This report will provide the EIB with a clearer understanding of the existing gaps, challenges, and support initiatives required for the region and the industry. Participating companies will have a unique opportunity to contribute directly to these findings and play a key role in shaping future recommendations and support mechanisms for the sector.
Institutional presence of the host city authority
Barcelona Investment Office / Barcelona City Council
Tuesday, 13 October 2026
13:00 - 16:00
Welcome, warm intros & Pre-assigned seating
Framing: E6 Session narrative & session focus
priority threads: Capital Gap, Regulatory Fragmentation/US Market Entry, Cross-Border Scaling with a parallel track run.
Break. Facilitators consolidate scores across pods.
Plenary synthesis: aggregated findings presented, then a moderated fireside with AffirmedRX responding live.
Closing: one named, public ask per pod, recorded on the spot.
Close
Agenda
-
Availability of venture and growth capital, financing gaps, ticket sizes, risk appetite and access to later-stage financing.
-
Regulatory fragmentation Duplicative approvals, certification, national divergence, compliance cost and time-to-market.
-
Ability to recruit, retain and relocate highly skilled technical and commercial talent.
-
Ability to sell to large industrial customers, utilities, healthcare systems and public-sector buyers.
-
Practical barriers to expanding products, operations, sales and infrastructure across EU and non-EU markets.
Objectives
RSVP
Methodology & Comparability
| Friction point | What it covers |
|---|---|
| 1. Capital Access | Financing gaps, ticket sizes, risk appetite, access to later-stage capital. |
| 2. Regulatory Fragmentation | Duplicative approvals, certification, export/dual-use classification, compliance cost. |
| 3. Talent | Ability to recruit, retain and relocate skilled technical and commercial talent. |
| 4. Anchor-Corporate / Procurement Access | Ability to sell to large industrial or public-sector buyers. |
| 5. Cross-Border Scaling | Barriers to expanding products, operations or infrastructure across markets. |
| Score | Label | Quick anchor |
|---|---|---|
| 1 | Negligible | Mentioned, no material effect in last 24 months. |
| 2 | Minor | Delay/cost but no strategy change (<1 month, <€50k). |
| 3 | Moderate | Forced a change in strategy/timeline/market (1-6 months, €50k-€500k). |
| 4 | Severe | Blocked a specific funding round, contract, hire, or market entry. |
| 5 | Structural | Existential/repeated constraint; company would relocate or has. |
Allocated Seats for Strategy Lab
1 seat per company | including confirmed & TBC participants
| Sanofi | Lukemia Research Institute | Oryzon | Barcelona City Council |
| IRTA | Sequentia Biotech | Braingaze | Inbrain Neuroelectronics |
| bpsynergies.eu | Aelix Therapeutics | BioNext Consulting | HAY pharma AG |
| Esteve | Ferrer | Reig Jofre | Inbiomotion |
| Aortyx | Pangaea Oncology | Devicare | MiMARK |
| Iproteos S.L. - merged | Vall d'Hebron Inst. of Oncology | Oxolife S.L. | Telomere Therapeutics S.L. |
| IrsiCaixa / Aelix Therapeutics | Aelix Therapeutics S.L. | Leukos Biotech S.L. | IRTA-CReSA |
| IBEC (Inst. Bioengineering of Cat.) | Valentia BioPharma S.L. |
FAQ
About the Program
-
The E6 Concord Four Labs Program is a series of closed-door working sessions run by the World Technology Congress under the Sovereign Vanguard initiative. Each city Lab gathers technology SMEs, investors and local partners to surface structured, comparable evidence on the real barriers to scaling in Europe. Findings from all four cities feed into the SME Sovereignty Gap Index and a consolidated evidence base submitted to the European Investment Bank (EIB), and a more consolidated version will be shared with other EU-wide institutional funds. (The program is independently commissioned and funded by Sovereign Collective Institute and World Technology Congress and is in no way associated with or endorsed by the EIB).
-
WTC's aim is to cover every E6 country and run labs in orbit countries too, building toward full EU coverage ahead of the Lake Como summit in April. This is being rolled out in phases rather than all at once.
Phase 1, October 2026, covers four cities:
Munich, 6 October 2026, Sector focus: Quantum Computing & Chips
Bratislava, 8 October 2026, Physical AI, Mobility, Manufacturing & Automation
Barcelona, 13 October 2026, Life Sciences, Healthcare, Biotech & Pharma
Turin, 15 October 2026, Space Tech, Advanced Materials & Strategic Supply Chains (final lab of Phase 1)
Phase 2 will be in January/February 2027; it will expand to additional cities, continuing toward full EU coverage before Lake Como. If you've heard a city mentioned that isn't in the table above (for example, Zagreb), that most likely reflects a later phase rather than an error - check with your WTC contact for the current phase-by-phase list, since it will keep expanding over the coming months.
-
A severity-scored friction map per city, comparable across all four, plus a Consolidated Asks section grouping every named ask by the institution that can act on it (an EIB instrument, an EU regulatory body, a national ministry) rather than by city, designed to be genuinely actionable, not just descriptive.
For SME / Company Participants
-
A decision-maker with direct, first-hand knowledge of the barrier being discussed, not a delegate sent to observe and report back. The right title depends on stage: for an early-stage company, the founder or co-founder is usually right, since they embody both the commercial and technical decisions. For a later-stage SME, send whoever owns the friction point most likely to come up: CEO or CFO for capital and procurement stories, CTO for regulatory or certification-heavy ones. If you're an anchor-corporate rather than an SME, a Head of Innovation or Strategic Partnerships is often a better fit than the CEO, since that's typically the person who actually interfaces with SME procurement.
Send one person, not a delegation. Table seats are scarce; roughly 3-5 companies share a table and 75 minutes total, so a second attendee from the same company doesn't add depth; it takes a seat from someone else's.
-
Bring one or two concrete, real examples of a barrier that slowed your growth, financing, hiring, or scaling- not a general view of the operating environment, and not a pitch. Quantify the impact where you can (time lost, € cost, a contract or hire lost). End with one specific, named ask.
-
Depending on the scoring topics, roughly between 9-15 minutes of table time within the breakout block, shared across five friction-point threads discussed by the whole table together; not five separate slots for your company alone.
-
Only if you opt-in. By default, no. Evidence is reported sector- and stage-anonymized (e.g. "Series A robotics OEM"). You may opt in to named attribution for a specific quote, confirmed individually and in writing before publication.
-
Where AI-assisted transcription is used to support real-time synthesis, we collect your consent individually before any device is switched on, using an EU-hosted tool. Raw notes and recordings stay internal to WTC and are not shared with local partners, investors, or the EIB in unprocessed form.
-
You'll receive a one-page pre-event briefing, personalized to your company, roughly two weeks ahead of your session, it suggests which friction points are likely your sharpest and asks you to prepare a quantified example and a proposed ask in advance.
-
Each sector table names one specific, institutionally-addressed ask by the end of the session; e.g. a named EIB instrument, an EU-wide regulatory sandbox standard, or a national procurement mandate. Vague asks ("more support", "less regulation") aren't accepted; the facilitator will push for an institution and a mechanism.
For Investors & Ecosystem Participants
-
To respond directly to the financing and scaling problems SMEs describe, and help distinguish firm-specific issues from structural market gaps.
-
Please don't. You will have plenty of opportunities outside the session. The facilitator will redirect a pitch back into a question for the founders. Your value in the room is reacting to what you hear, not presenting.